ClinicalTrials.gg
RecruitingNCT07508787MODERNIZE1Updated Nov 12, 2026

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

A Phase 2 interventional study of Siplizumab and Rabbit anti-thymocyte globulin in Renal Transplant Failure and Rejection, sponsored by ITB-Med LLC. Recruiting at 27 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 12, 2026First sites in Brazil and SpainSponsor changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Read the detailed description

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

02

Conditions studied

  • Renal Transplant Failure and Rejection
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time \< 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of , defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of .

Exclusion criteria

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for or surface antigen. Participants who are seropositive for virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Low dose siplizumab

    Drug: Siplizumab

  • Experimental
    High dose siplizumab

    Drug: Siplizumab

  • Active comparator
    Rabbit anti-thymocyte globulin

    Drug: Rabbit anti-thymocyte globulin

Interventions

  • A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

    Also known as: TCD601

  • An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

    Also known as: Thymoglobulin

06

What researchers measure

Primary outcomes

  1. Assessment of the safety of 2 dose levels of siplizumab versus rATG.

    Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

    Time frame: 12 months

Secondary outcomes

  1. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    * Composite incidence of BPAR, death, graft loss, and loss-to-follow-up. * Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring). * Incidence of treated BPAR and steroid-resistant BPAR.

    Time frame: 12 months

  2. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    • Grade of BPAR.

    Time frame: 12 months

  3. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    • Severity of BPAR.

    Time frame: 12 months

  4. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    * Time to first BPAR for each participant. * Time to graft loss for each participant. * Time to death for each participant.

    Time frame: 12 months

  5. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    * Participant survival at 12 months. * Graft survival at 12 months.

    Time frame: 12 months

  6. Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.

    • Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

    Time frame: 12 months

  7. Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.

    Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

    Time frame: 12 weeks

  8. Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.

    Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

    Time frame: 12 weeks

  9. Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.

    Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

    Time frame: 12 months

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Apr 2, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Mar 28, 2028
CompletionEst.
Mar 28, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 1 site removed — first sites in Brazil and Spain. UC Davis Medical Center is now Recruiting
Show 21 added (12 United States, 6 Brazil, 3 Spain)
  • UMass Chan Medical Center · Worcester, United States
  • Henry Ford Health · Detroit, United States
  • Inova Fairfax Hospital · Falls Church, United States
  • Virginia Commonwealth University Health · Richmond, United States
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
  • Hospital Universitari Vall D'Hebron · Barcelona, Spain
  • Hospital Universitario Regional de Malaga · Málaga, Spain
  • Keck Hospital of the University of Southern California · Los Angeles, United States
  • University of California - Los Angeles, Connie Frank Kidney Transplant Center · Los Angeles, United States
  • University of Kansas Hospital · Kansas City, United States
  • Tulane Medical Center · Metairie, United States
  • New York Presbyterian - Columbia University Irving Medical School · New York, United States
  • New York Presbyterian - Weill Cornell Medical Center · New York, United States
  • Duke University Medical Center · Durham, United States
  • Santa Casa Demisericordia de Belo Horizonte · Belo Horizonte, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
  • Fundação Oswaldo Ramos - Hospital do Rim (HRIM) · São Paulo, Brazil
  • Hospital Universitario Reina Sofía · Córdoba, Spain
  • University of Kentucky Healthcare · Lexington, United States
  • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer · Porto Alegre, Brazil
  • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
Show 1 removed
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
across 3 updates, Oct 6, 2026 – Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Keck Hospital of the University of Southern California · Los Angeles, United StatesContact •••5542→•••7983
Nov 12, 2026
Sponsor
Nefro Avillion Clinical Development, LLC→ITB-Med LLC
Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    3 sites added
    Show 3 added (2 Brazil, 1 United States)
    • University of Kentucky Healthcare · Lexington, United States
    • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer · Porto Alegre, Brazil
    • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
    Sponsor Nefro Avillion Clinical Development, LLC→ITB-Med LLC
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Keck Hospital of the University of Southern California · Los Angeles, United StatesContact •••5542→•••7983
    + 2 other changes: identifiers and verification date
  2. Nov 3, 2026
    11 sites added, 1 site removed. UC Davis Medical Center is now Recruiting
    Show 11 added (7 United States, 3 Brazil, 1 Spain)
    • Keck Hospital of the University of Southern California · Los Angeles, United States
    • University of California - Los Angeles, Connie Frank Kidney Transplant Center · Los Angeles, United States
    • University of Kansas Hospital · Kansas City, United States
    • Tulane Medical Center · Metairie, United States
    • New York Presbyterian - Columbia University Irving Medical School · New York, United States
    • New York Presbyterian - Weill Cornell Medical Center · New York, United States
    • Duke University Medical Center · Durham, United States
    • Santa Casa Demisericordia de Belo Horizonte · Belo Horizonte, Brazil
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
    • Fundação Oswaldo Ramos - Hospital do Rim (HRIM) · São Paulo, Brazil
    • Hospital Universitario Reina Sofía · Córdoba, Spain
    Show 1 removed
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
  3. Oct 6, 2026
    7 sites added — first sites in Brazil and Spain
    Show 7 added (4 United States, 2 Spain, 1 Brazil)
    • UMass Chan Medical Center · Worcester, United States
    • Henry Ford Health · Detroit, United States
    • Inova Fairfax Hospital · Falls Church, United States
    • Virginia Commonwealth University Health · Richmond, United States
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa · São José do Rio Preto, Brazil
    • Hospital Universitari Vall D'Hebron · Barcelona, Spain
    • Hospital Universitario Regional de Malaga · Málaga, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07508787
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jun 29, 2026
Primary completion
Mar 28, 2028 (estimated)
Completion
Mar 28, 2028 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion